If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

The drugmaker – which was known as Mallinckrodt beforemerging with Endo and rebranding as Keenova last year – said that ...

Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic ...

Keenova Therapeutics plc, a leading US-focused branded therapeutics company, announced positive results from its phase 3 clinical trial of Xiaflex (collagenase clostridium histolyticum) for the ...

After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...

Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium ...